Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18281730 | 0.89 | FFAR1 (0.46) | ALDH1A1LMNA | |
| SCHEMBL18297064 | 0.86 | PREP (0.53) | L3MBTL1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL20296953 | 0.85 | ATM (0.42) | ATML3MBTL1 | |
| SCHEMBL18281715 | 0.82 | MITF (0.52) | ATMALDH1A1LMNATSHR | |
| SCHEMBL18297065 | 0.80 | NPSR1 (0.54) | L3MBTL1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL19947268 | 0.79 | ATM (0.47) | ATML3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL20595779 | 0.79 | CYP2D6 (0.61) | LMNATSHR | |
| SCHEMBL18281713 | 0.78 | CHRM3 (0.40) | ATML3MBTL1ALDH1A1 | |
| SCHEMBL19946992 | 0.77 | L3MBTL1 (0.39) | ATML3MBTL1 | |
| SCHEMBL3998594 | 0.77 | KMT2A (0.49) | ALDH1A1LMNAMEN1KMT2ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981704-B2 | Decarboxylative conjugate additions and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-05-14 | — | — | US | disclosed |
| US-20220002342-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2022-01-06 | — | — | US | disclosed |
| US-11136349-B2 | Decarboxylative conjugate additions and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2021-10-05 | — | — | US | disclosed |
| US-20180179248-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2018-06-28 | — | — | US | disclosed |
| WO-2016196931-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179248-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | PTMS, DNPEP, QPCT | ATM 2850/4885L3MBTL1 2802/4885ALDH1A1 436/4885 |
| US-20220002342-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | PTMS, DNPEP, QPCT | ATM 2850/4885L3MBTL1 2802/4885ALDH1A1 436/4885 |
| US-11981704-B2 | Decarboxylative conjugate additions and applications thereof | PTMS, DNPEP, QPCT | ATM 2850/4885L3MBTL1 2802/4885ALDH1A1 436/4885 |
| US-11136349-B2 | Decarboxylative conjugate additions and applications thereof | PTMS, DNPEP, QPCT | ATM 2850/4885L3MBTL1 2802/4885ALDH1A1 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.